HOUSE COMMERCE COMMITTEE FDA REFORM MARKUP WILL START AFTER AUGUST RECESS; IF S 830 IS USED AS BLUEPRINT, BILL COULD PASS BEFORE USER FEE DEADLINE
The House will have approximately one month after the August Congressional recess to complete the legislative process on FDA reform, according to the current schedule for the bill set by the House Commerce Committee.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth